Results 31 to 40 of about 1,866 (169)

An evaluation of bimekizumab for the treatment of hidradenitis suppurativa

Expert Opinion on Biological Therapy
Introduction Until recently, the biological treatment options for hidradenitis suppurativa (HS) were largely restricted to adalimumab and secukinumab. In 2024, bimekizumab, an IL-17A and IL-17F antibody was introduced to the clinical practice.
Tomasz Skrzypczak, A. Skrzypczak, Ł. Matusiak, J. Szepietowski   +3 more
semanticscholar   +3 more sources

Bimekizumab: A Review in Psoriatic Arthritis

Drugs
Although several biological disease-modifying antirheumatic drugs (bDMARDs), including interleukin (IL)-17A inhibitors, are approved for psoriatic arthritis, the treatment of this disease remains suboptimal. Bimekizumab (Bimzelx®), a dual IL-17A and IL-17F inhibitor, is approved in the EU, Great Britain and Japan for the treatment of psoriatic ...
Tina Nie, Matt Shirley
openaire   +3 more sources

Long-term safety and efficacy of bimekizumab in axial spondyloarthritis: 2-year results from two phase 3 studies

Rheumatology
Objectives Bimekizumab, a monoclonal IgG1 antibody that selectively inhibits IL-17F in addition to IL-17A, previously demonstrated efficacy and was well tolerated to 1 year in patients with non-radiographic (nr-) and radiographic (r-) axial ...
X. Baraliakos, A. Deodhar, D. M. van der Heijde, F. E. Van den Bosch, M. Magrey, W. Maksymowych, Tetsuya Tomita, Hu-Ji Xu, U. Massow, T. Vaux, C. Prajapati, Myriam Manente, Alexander Marten, L. Gensler   +13 more
semanticscholar   +1 more source

Bimekizumab efficacy and safety through 3 years in patients with moderate to severe plaque psoriasis: Long-term results from the BE RADIANT phase 3b trial open-label extension period.

British Journal of Dermatology
BACKGROUND Overexpression of interleukin (IL)-17A and IL-17F significantly influences psoriasis pathology. Until recently, biologics targeting IL-17A alone, like secukinumab, were used to treat psoriasis.
Richard B. Warren, M. Lebwohl, D. Thaçi, M. Gooderham, Andreas Pinter, C. Paul, P. Gisondi, Balint Szilagyi, K. White, D. Deherder, F. Staelens, Jérémy Lambert, B. Strober   +12 more
semanticscholar   +1 more source

SA64 Comparative Effectiveness of Bimekizumab in Patients with Psoriatic Arthritis: Results from a Systematic Literature Review and Network Meta-Analysis

, 2023
Objectives: To compare the relative efficacy and safety of bimekizumab, a selective inhibitor of interleukin (IL)-17F in addition to IL-17A, against approved biologic- and targeted synthetic disease-modifying anti-rheumatic drugs (b/tsDMARDs) for ...
D. Willems, Mease, PJ, D.D. Gladman, Taieb, V, J.F Merola, L.C Coates, Willems, D, Nash, P, P.J Mease, A.R Prickett, Laliman-Khara, V, P. Nash, V. Laliman-Khara, Coates, LC, Prickett, AR, S. Grieve, Gladman, DD, Grieve, S, V. Taieb, Merola, JF   +19 more
core   +1 more source

Bimekizumab durability of efficacy through 196 weeks and safety through 4 years in patients with moderate to severe plaque psoriasis: Results from the BE BRIGHT open-label extension trial.

Journal of American Academy of Dermatology
BACKGROUND Patients with moderate to severe psoriasis experience significant burden on quality of life. Long-term management with latest-generation biologics can facilitate sustained complete skin clearance and improved patient well-being. OBJECTIVE To
A. Blauvelt, Richard G. Langley, M. Lebwohl, B. Strober, Richard B. Warren, Luís Puig, Akimichi Morita, Kenneth B. Gordon, Pablo Fernández-Peñas, Sarah Kavanagh, J. López-Pinto, Jérémy Lambert, B. Hoepken, D. Deherder, N. Cross, D. Thaçi   +15 more
semanticscholar   +1 more source

Long-term safety and sustained efficacy of bimekizumab in patients with ankylosing spondylitis (radiographic axial spondyloarthritis): 5-year results from BE AGILE (phase 2b) and its open-label extension

RMD Open
Objective Assess long-term safety, tolerability and efficacy of bimekizumab in ankylosing spondylitis (radiographic axial spondyloarthritis (r-axSpA)). Methods Patients with active r-axSpA completing the dose-ranging 48-week randomised controlled trial ...
A. Deodhar, V. Navarro-Compán, D. Poddubnyy, L. Gensler, S. Ramiro, Tetsuya Tomita, H. Marzo-Ortega, C. Fleurinck, T. Vaux, U. Massow, N. de Peyrecave, D. M. van der Heijde, X. Baraliakos   +12 more
semanticscholar   +1 more source

Risk of Cancer According to Duration of Targeted Therapy Exposure in Spondyloarthritis: A Nationwide Cohort Study From the French Health Insurance Database

Arthritis &Rheumatology, EarlyView.
Objective To assess the association between duration of targeted therapy exposure and cancer risk in patients with spondyloarthritis (SpA), including those with psoriatic arthritis, axial SpA, and other subtypes. Methods This nationwide cohort study used the French health insurance database to identify adults with SpA initiating a targeted therapy ...
Karine Tankovic, Pascal Claudepierre, Tat Thang Vo, Tran Trong Khoi Le, Siham Iggui, Laetitia Penso, Emilie Sbidian, Laura Pina Vegas   +7 more
wiley   +1 more source

Effectiveness and safety of bimekizumab for the treatment of plaque psoriasis: a real-life multicenter study—IL PSO (Italian landscape psoriasis)

Frontiers in Medicine, 2023
IntroductionBimekizumab is a monoclonal antibody that targets Interleukin-17 A and F, approved for the treatment of moderate-to-severe plaque psoriasis.
Luigi Gargiulo, Luigi Gargiulo, Alessandra Narcisi, Luciano Ibba, Luciano Ibba, Anna Balato, Luca Bianchi, Pina Brianti, Dario Buononato, Martina Burlando, Giacomo Caldarola, Giacomo Caldarola, Anna Campanati, Elena Campione, Carlo G. Carrera, Andrea Carugno, Andrea Carugno, Antonio Cristaudo, Francesco Cusano, Paolo Dapavo, Annunziata Dattola, Clara De Simone, Clara De Simone, Francesca M. Gaiani, Paolo Gisondi, Alessandro Giunta, Francesco Loconsole, Vincenzo Maione, Edoardo Mortato, Angelo V. Marzano, Angelo V. Marzano, Martina Maurelli, Matteo Megna, Santo R. Mercuri, Annamaria Offidani, Diego Orsini, Aurora Parodi, Giovanni Pellacani, Luca Potestio, Pietro Quaglino, Antonio G. Richetta, Francesca Romano, Paolo Sena, Marina Venturini, Piergiorgio Malagoli, Antonio Costanzo, Antonio Costanzo   +46 more
doaj   +1 more source

Bimekizumab for the treatment of moderate to severe psoriasis: a real-world experience over 52 weeks from two Italian dermatology clinics

Journal of dermatological treatment (Print)
Purpose: Psoriasis is a chronic, immune-mediated inflammatory skin condition marked by erythematous, scaly plaques. This retrospective observational study evaluated the long-term efficacy and safety of bimekizumab, a dual IL-17A and IL-17F inhibitor, in ...
E. Mortato, F. Artosi, C. Borselli, I. Compagnucci, Antonia Rivieccio, C. Lanna, S. Lambiase, R. Gaeta Shumak, F. Loconsole, L. Bianchi, E. Campione   +10 more
semanticscholar   +1 more source